See more : Inland Printers Limited (INLANPR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ATRenew Inc. (RERE) Income Statement Analysis – Financial Results
- S.S. Lazio S.p.A. (SSL.MI) Income Statement Analysis – Financial Results
- Nubian Resources Ltd. (NBR.V) Income Statement Analysis – Financial Results
- The a2 Milk Company Limited (ATM.NZ) Income Statement Analysis – Financial Results
- MSP Recovery, Inc. (MSPRW) Income Statement Analysis – Financial Results
Compugen Ltd. (CGEN)
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.46M | 7.50M | 6.00M | 2.00M | 0.00 | 17.80M | 0.00 | 712.00K | 9.28M | 12.37M | 3.55M | 242.00K | -424.00K | 1.12M | 250.00K | 338.00K | 180.00K | 215.00K | 646.00K | 4.03M | 8.83M | 11.10M | 11.36M | 6.89M | 3.24M |
| Cost of Revenue | 2.00M | 975.00K | 680.00K | 60.00K | 989.00K | 1.03M | 1.59M | 223.00K | 1.63M | 3.34M | 2.51M | 201.00K | 424.00K | 224.00K | 0.00 | 7.00K | 0.00 | 6.00K | 148.00K | 1.10M | 2.28M | 2.82M | 3.46M | 478.00K | -769.00K |
| Gross Profit | 31.46M | 6.53M | 5.32M | 1.94M | -989.00K | 16.77M | -1.59M | 489.00K | 7.64M | 9.02M | 1.04M | 41.00K | -848.00K | 891.00K | 250.00K | 331.00K | 180.00K | 209.00K | 498.00K | 2.93M | 6.55M | 8.28M | 7.91M | 6.41M | 4.01M |
| Gross Profit Ratio | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | 200.00% | 79.91% | 100.00% | 97.93% | 100.00% | 97.21% | 77.09% | 72.68% | 74.22% | 74.60% | 69.59% | 93.06% | 123.76% |
| Research & Development | 34.47M | 30.65M | 28.69M | 22.76M | 19.82M | 30.32M | 28.58M | 24.55M | 21.25M | 15.07M | 12.28M | 9.44M | 6.78M | 5.23M | 5.05M | 8.75M | 8.39M | 9.81M | 10.47M | 12.32M | 13.31M | 14.17M | 15.98M | 12.17M | 6.68M |
| General & Administrative | 9.73M | 10.32M | 10.86M | 9.81M | 8.41M | 8.04M | 7.63M | 7.35M | 6.01M | 5.45M | 4.85M | 3.46M | 4.59M | 2.91M | 2.15M | 3.50M | 0.00 | 0.00 | 0.00 | 3.61M | 4.38M | 5.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 244.00K | 932.00K | 842.00K | 871.00K | 651.00K | 1.63M | 1.19M | 1.17M | 1.31M | 838.00K | 962.00K | 684.00K | 610.00K | 633.00K | 681.00K | 996.00K | 0.00 | 0.00 | 0.00 | 5.54M | 6.57M | 3.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.98M | 11.25M | 11.70M | 10.68M | 9.06M | 9.68M | 8.82M | 8.52M | 7.32M | 6.29M | 5.81M | 4.14M | 5.20M | 3.54M | 2.83M | 4.50M | 4.25M | 4.39M | 4.91M | 6.19M | 7.46M | 9.15M | 10.95M | 9.18M | 4.32M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -523.00K | -811.00K | -588.00K | 281.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.82M | 18.44M | 13.89M | 0.00 | 0.00 | 1.86M |
| Operating Expenses | 44.45M | 41.90M | 40.39M | 33.44M | 28.88M | 39.99M | 37.41M | 33.07M | 28.56M | 21.36M | 18.08M | 13.58M | 11.98M | 8.77M | 7.88M | 13.24M | 12.64M | 14.20M | 15.38M | 18.50M | 20.77M | 23.32M | 26.92M | 21.35M | 12.85M |
| Cost & Expenses | 46.45M | 42.87M | 41.07M | 33.50M | 28.88M | 41.03M | 37.41M | 33.30M | 30.20M | 24.70M | 20.59M | 13.78M | 11.98M | 8.99M | 7.88M | 13.25M | 12.64M | 14.21M | 15.52M | 19.60M | 23.04M | 26.14M | 30.38M | 21.83M | 12.09M |
| Interest Income | 3.24M | 1.74M | 894.00K | 1.77M | 935.00K | 643.00K | 523.00K | 728.00K | 815.00K | 346.00K | 169.00K | 301.00K | 0.00 | 0.00 | 0.00 | 502.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 31.00K | 27.00K | 25.00K | 42.00K | 32.00K | 620.00K | 508.00K | 705.00K | 755.00K | 330.00K | 141.00K | 240.00K | -306.00K | 241.00K | 65.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 476.00K | 482.00K | 461.00K | 715.00K | 989.00K | 1.39M | 1.59M | 1.48M | 1.11M | 658.00K | 370.00K | 299.00K | 179.00K | 201.00K | 264.00K | 477.00K | 633.00K | 996.00K | 2.39M | 1.76M | 2.68M | 2.90M | 4.28M | 4.99M | 1.86M |
| EBITDA | -12.52M | -35.37M | -34.61M | -31.50M | -27.04M | -21.83M | -35.46M | -31.10M | -19.81M | -12.34M | -17.04M | -13.27M | -11.81M | -7.68M | -7.37M | -12.03M | -11.83M | -13.08M | -12.49M | -13.81M | -12.20M | -12.15M | -14.74M | -9.94M | -6.99M |
| EBITDA Ratio | -37.41% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,891.51% | -767.09% | -4,566.00% | -3,835.80% | -6,578.33% | -6,095.81% | -1,967.49% | -353.89% | -138.26% | -109.45% | -126.73% | -145.13% | -215.32% |
| Operating Income | -12.99M | -35.37M | -35.07M | -31.50M | -28.88M | -23.23M | -37.41M | -32.58M | -20.92M | -12.34M | -17.04M | -13.54M | -11.98M | -7.88M | -7.63M | -12.91M | -12.46M | -13.99M | -14.88M | -15.58M | -14.22M | -15.04M | -19.02M | -16.18M | -8.85M |
| Operating Income Ratio | -38.83% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,825.24% | -706.55% | -3,051.60% | -3,820.12% | -6,922.22% | -6,508.37% | -2,303.10% | -386.81% | -161.07% | -135.57% | -167.42% | -234.74% | -273.34% |
| Total Other Income/Expenses | 3.21M | 1.74M | 871.00K | 1.80M | 820.00K | 628.00K | 339.00K | 1.10M | 1.15M | 1.76M | 3.46M | -86.00K | 0.00 | 675.00K | 3.79M | 401.00K | 1.00M | 1.94M | 900.00K | 1.86M | 2.77M | 2.84M | -348.00K | 1.30M | -18.00K |
| Income Before Tax | -9.78M | -33.64M | -34.20M | -29.70M | -28.06M | -22.60M | -37.07M | -31.49M | -19.77M | -10.73M | -13.58M | -13.63M | -12.00M | -7.44M | -3.84M | -12.51M | -11.46M | -13.88M | -14.66M | -15.14M | -13.55M | -13.40M | -19.37M | -14.87M | -8.87M |
| Income Before Tax Ratio | -29.24% | -448.48% | -570.05% | -1,484.90% | 0.00% | -126.96% | 0.00% | -4,422.19% | -213.14% | -86.80% | -382.73% | -5,631.40% | 2,831.13% | -667.62% | -1,537.20% | -3,701.48% | -6,365.56% | -6,457.67% | -2,269.35% | -375.94% | -153.57% | -120.79% | -170.48% | -215.85% | -273.90% |
| Income Tax Expense | 8.97M | 58.00K | -1.33M | -2.44M | -722.00K | -1.26M | -678.00K | 20.00K | 390.00K | 360.00K | 500.00K | -416.00K | 331.00K | -1.35M | -7.58M | -37.00K | 32.00K | -1.08M | -1.12M | -2.29M | -3.44M | -2.84M | -3.53M | -1.59M | -701.00K |
| Net Income | -18.75M | -33.69M | -32.87M | -27.26M | -27.34M | -22.60M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12.00M | -7.20M | -3.83M | -12.53M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.20M | -15.14M | -13.40M | -8.13M |
| Net Income Ratio | -56.05% | -449.25% | -547.88% | -1,363.00% | 0.00% | -126.96% | 0.00% | -4,425.00% | -217.34% | -89.71% | -396.82% | -5,631.40% | 2,831.13% | -646.01% | -1,532.40% | -3,706.21% | -6,730.00% | -6,055.81% | -2,163.78% | -340.75% | -129.64% | -109.98% | -133.31% | -194.51% | -251.13% |
| EPS | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| EPS Diluted | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| Weighted Avg Shares Out | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 47.81M | 38.87M | 35.84M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
| Weighted Avg Shares Out (Dil) | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.
Compugen Reports Third Quarter 2023 Results
Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy Clinical data presented at SITC 2023 reinforces COM701 (anti-PVRIG) mediated anti-tumor activity in...
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses > 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of baseline inflammatory status...
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that on November 3, 2023, it received a notification letter from the Listing...
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Anti-IL-18BP antibody immune modulation is confined to the tumor site expected to have a favorable therapeutic window compared to engineered cytokines Data to...
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that the Company will release its third quarter 2023 financial results on Tuesday,...
These Israeli pharmaceutical stocks are down in the wake of Hamas attack
Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.
Compugen to Present at Single Cell Genomics 2023 Meeting
HOLON, Israel , Oct. 3, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, it will present innovative single-cell approaches and high resolution single cell spatial transcriptomics data...
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
HOLON, Israel , Oct. 2, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Japanese Patent Office has granted Compugen a patent for treating cancer with...
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
HOLON, Israel , Sept. 27, 2023 /PRNewswire/ -- Compugen Ltd.
Source: https://incomestatements.info
Category: Stock Reports